Patents Assigned to Tularik Inc.
  • Pentafluorobenzenesulfonamides and analogs
    Patent number: 6316484
    Abstract: The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: November 13, 2001
    Assignee: Tularik Inc.
    Inventors: John A. Flygare, Julio Cesar Medina, Bei Shan, David Louis Clark, Terry J. Rosen
  • LXR modulators
    Patent number: 6316503
    Abstract: The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The compounds and compositions find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: November 13, 2001
    Assignee: Tularik Inc.
    Inventors: Leping Li, Julio C. Medina, Kevin Lustig, Bei Shan, Hirohiko Hasegawa, Serena T. Cutler, Jiwen Liu, Liusheng Zhu
  • Detection method for monitoring &bgr; tubulin isotype specific modification
    Patent number: 6306615
    Abstract: This invention relates to monoclonal antibodies that recognize modified &bgr;-tubulin isotypes, methods of using such antibodies to detect modified &bgr;-tubulin isotypes, methods of using such antibodies to monitor &bgr;-tubulin modifying agents administered to a patient, methods of using such antibodies to isolate modified &bgr;-tubulin, and methods of detecting the anti-modified &bgr;-tubulin antibodies.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: October 23, 2001
    Assignee: Tularik Inc.
    Inventors: Holger Beckmann, Edit Santha
  • HIV integrase inhibitors
    Patent number: 6306891
    Abstract: Nitrogen-containing heteroaryl dioxo-butyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: October 23, 2001
    Assignees: Merck & Co., Inc., Tularik Inc.
    Inventors: Harold G. Selnick, Melissa Egbertson, Daria Jean Hazuda, James P. Guare, Jr., John S. Wai, Steven D. Young, David L. Clark, Julio C. Medina
  • PPARgamma modulators
    Publication number: 20010027200
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Application
    Filed: December 19, 2000
    Publication date: October 4, 2001
    Applicant: Tularik Inc.
    Inventors: Fabienne De la Brouse-Elwood, Jin-Long Chen, Timothy D. Cushing, John A. Flygare, Jonathan B. Houze, Juan C. Jaen, Lawrence R. McGee, Shi-Chang Miao, Steven Marc Rubenstein, Patrick C. Kearney
  • Arylsulfonanilide ureas
    Publication number: 20010027211
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Application
    Filed: February 21, 2001
    Publication date: October 4, 2001
    Applicant: Tularik Inc.
    Inventor: Jonathan B. Houze
  • Recombinant polynucleotides encoding CYP7 promoter-binding factors
    Patent number: 6297019
    Abstract: The invention provides methods and compositions relating to CPF proteins which regulate transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed CPF encoding nucleic acids or purified from human cells. The invention provides isolated CPF hybridization probes and primers capable of specifically hybridizing with the disclosed CPF genes, CPF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: October 2, 2001
    Assignees: Tularik Inc., Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Bei Shan, Masahiro Nitta
  • TRAF inhibitors
    Patent number: 6294348
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: September 25, 2001
    Assignees: Genentech Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • Substituted benzene compounds as antiproliferative and cholesterol lowering action
    Patent number: 6284923
    Abstract: The invention provides compounds, compositions and methods relating to novel electrophilic aromatic derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: September 4, 2001
    Assignee: Tularik INC
    Inventors: Julio Cesar Medina, David Louis Clark, John A. Flygare, Terry J. Rosen, Bei Shan
  • Pyrimidine derivatives
    Publication number: 20010018436
    Abstract: Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.
    Type: Application
    Filed: December 15, 2000
    Publication date: August 30, 2001
    Applicant: Tularik Inc.
    Inventors: Timothy D. Cushing, Heather L. Mellon, Juan C. Jaen, John A. Flygare, Shi-Chang Miao, Xiaoqi Chen, Jay P. Powers
  • Arylsulfonanilide phosphates
    Publication number: 20010018430
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Application
    Filed: February 7, 2001
    Publication date: August 30, 2001
    Applicant: Tularik, Inc.
    Inventor: Jonathan B. Houze
  • Interleukin-1 receptor accessory proteins, nucleic acids and methods
    Patent number: 6280955
    Abstract: The invention provides methods and compositions relating to IL-1RAcP proteins that regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IL-1RAcP encoding nucleic acids purified from human cells. The invention provides isolated IL-1RAcP hybridization probes and primers capable of specifically hybridizing with the disclosed IL-1RAcP genes, IL-1RAcP-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: August 28, 2001
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • IRAK3 polypeptides and methods
    Patent number: 6262228
    Abstract: The invention provides methods and compositions relating to a novel kinase, IRAK3. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IRAK3 encoding nucleic acids or purified from human cells. The invention provides isolated IRAK3 hybridization probes and primers capable of specifically hybridizing with the disclosed IRAK3 genes, IRAK3-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: July 17, 2001
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • UCP3 genes
    Patent number: 6248561
    Abstract: The invention provides methods and compositions relating to a novel family of UCP3 polypeptides and related nucleic acids involved in metabolic regulation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed mUCP3 encoding nucleic acids or purified from mammalian cells. The invention provides isolated mUCP3 hybridization probes, knock-out/in constructs and primers capable of specifically hybridizing with the disclosed mUCP3 genes, mUCP3-specific binding agents such as specific antibodies, animals and cells modified with the subject mUCP3 nucleic acids, and methods of making and using the subject compositions in the biopharmaceutical industry.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: June 19, 2001
    Assignee: Tularik Inc.
    Inventors: Ning Zhang, M. Catherine Amaral, Jin-Long Chen
  • Regulators of apoptosis
    Patent number: 6242569
    Abstract: The invention provides methods and compositions relating to apopotosis regulating proteins, known as Casper proteins, and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed Casper encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed Casper gene, Casper-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: June 5, 2001
    Assignee: Tularik, Inc.
    Inventors: Hong-Bing Shu, David V. Goeddel
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235492
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235513
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235512
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
    Patent number: 6232068
    Abstract: The present invention relates to anti-heteronucleic acid antibodies and their uses for detection of RNA-DNA duplexes on arrays. The invention provides a method for detection of total cellular RNA hybridization on microarrays, thus obviating the need for isolation of the poly(A)+ fraction.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: May 15, 2001
    Assignees: Rosetta Inpharmatics, Inc., Tularik Inc.
    Inventors: Peter S. Linsley, Patrick Baeuerle
  • Arylsulfonanilide ureas
    Patent number: 6214880
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: April 10, 2001
    Assignee: Tularik Inc.
    Inventor: Jonathan B. Houze